IGF-1 as a Research Marker

Researchers running HGH or secretagogue protocols frequently have no feedback loop. They’re dosing on schedule and observing subjective outcomes — sleep quality, body composition over time, recovery — without any objective measure of whether the protocol is producing the expected physiological response. IGF-1 bloodwork closes that loop. It is the single most reliable proxy marker for growth hormone axis activity currently available outside a clinical setting.

Why IGF-1 and not direct GH measurement

Growth hormone is released in pulses — primarily during slow-wave sleep, with additional pulses in response to exercise, fasting, and specific stimuli. A single serum GH measurement is nearly meaningless as a protocol marker because the result depends entirely on where in the pulsatile cycle the draw happens. You could measure GH at its overnight peak (15–20 ng/mL) or at its daytime nadir (0.1–0.5 ng/mL) and both readings are normal.

IGF-1 is produced in the liver in response to cumulative GH exposure. It has a half-life of approximately 12–15 hours and reflects integrated GH activity over the preceding days rather than a point-in-time snapshot. A morning IGF-1 draw, taken in a standardized fasted state, gives researchers a stable, comparable number across measurement points.

Standardizing the draw

IGF-1 is sensitive to recent food intake, exercise, and sleep quality. A researcher who draws in a fasted state at 8am on one occasion and in a fed state at 2pm after a heavy training session on the next occasion is not measuring the same thing. Across a research protocol with multiple measurement points, standardization of draw conditions is as important as the measurement itself.

Standard research protocol: fasted 8–12 hours, no intense exercise in the preceding 24 hours, draw in the morning. This minimizes the major sources of within-subject variability. Consistent timing relative to last secretagogue dose also matters — draw at the same interval post-injection across all measurement points.

IGF-1 alone isn’t the full picture

IGFBP-3 (insulin-like growth factor binding protein 3) is the primary carrier protein for IGF-1 in circulation. The IGF-1 to IGFBP-3 ratio gives researchers a more accurate picture of bioavailable IGF-1 than IGF-1 in isolation — a high IGF-1 with proportionally high IGFBP-3 suggests less free IGF-1 available for receptor binding than the raw number implies.

For most observational research tracking protocol response rather than clinical safety, IGF-1 alone is sufficient. IGFBP-3 becomes relevant when IGF-1 numbers are inconsistently high relative to the protocol being run, or when the researcher is attempting to characterize bioavailability rather than simply confirming GH axis activation.

Fasting insulin and glucose should be included in any comprehensive GH protocol bloodwork, as GH has counter-regulatory effects on insulin sensitivity that warrant monitoring in longer or higher-dose research contexts.